Leishmaniasis Cell Models for Research

Leishmaniasis is a neglected tropical disease caused by protozoan parasites of the genus Leishmania, transmitted by phlebotomine sandflies. According to WHO (2023), an estimated 700,000 to 1 million new cases of cutaneous leishmaniasis (CL) occur annually, while visceral leishmaniasis (VL) affects 50,000 to 90,000 people per year, with a case fatality rate of over 95% if untreated. The disease is endemic in 98 countries, with the highest burden in Brazil, East Africa, India, and the Mediterranean basin. Risk factors include poverty, malnutrition, immunosuppression (e.g., HIV co-infection), and environmental changes. Unlike many cancers, leishmaniasis does not have a 5-year survival metric; however, VL mortality without treatment exceeds 95%, and even with treatment, mortality can reach 10-20% in resource-limited settings. Post-kala-azar dermal leishmaniasis (PKDL) occurs in 5-10% of treated VL cases and serves as a reservoir for transmission. The global burden is estimated at 1.7 million disability-adjusted life years (DALYs), underscoring the urgent need for new therapeutics and vaccines.

Leishmania species offer a unique model for studying host-pathogen interactions, immune evasion, and drug resistance due to their well-characterized life cycle (promastigote in sandfly, amastigote in mammalian macrophages) and genetic tractability. Key species include L. donovani (VL), L. major (CL), L. braziliensis (mucocutaneous), and L. mexicana (CL). Public datasets such as those from the Wellcome Sanger Institute, NCBI BioProject, and TriTrypDB provide genomic, transcriptomic, and proteomic resources. Open questions include the mechanisms of drug resistance (e.g., antimony, miltefosine), host immune modulation, and the role of asymptomatic carriers. The parasite's ability to persist in macrophages makes it an excellent system for studying intracellular survival and therapeutic targeting. Additionally, the rise of CRISPR-Cas9 technology has enabled precise genetic manipulation, facilitating functional genomics and target validation.

Leishmaniasis is not a carcinogenic disease, but the parasite manipulates host signaling pathways to establish infection and evade immunity. Key pathways include:

• • Host immune evasion:

1. Inhibition of JAK/STAT signaling: Leishmania prevents IFN-gamma-induced macrophage activation by degrading STAT1 or inducing SOCS proteins.

2. Modulation of NF-kB: Parasite-derived proteases (e.g., GP63) cleave NF-kB p65, reducing pro-inflammatory cytokine production.

3. Activation of PI3K/AKT: Promotes anti-apoptotic signals in infected macrophages, enhancing parasite survival.

4. Wnt/beta-catenin signaling: Leishmania activates Wnt in host cells, which may suppress immune responses and promote parasite persistence.

• • Parasite survival mechanisms:

1. Antioxidant defense: Tryparedoxin peroxidase and superoxide dismutase neutralize host reactive oxygen species.

2. Arginase activation: Depletes L-arginine, limiting nitric oxide production by host macrophages.

3. Glycosylphosphatidylinositol (GPI) anchors: Modulate host cell signaling and immune recognition.

Leishmania parasites exhibit genomic plasticity, including aneuploidy, gene amplification, and copy number variations (CNVs) that drive drug resistance and virulence. The table below summarizes key genes and alterations from genomic studies (e.g., TriTrypDB, NCBI).

Note: Frequencies vary by species and geographic region. Data compiled from TriTrypDB and published genomic studies (e.g., PMID: 28970485).

Leishmania infection deregulates multiple host signaling networks to promote survival and immune evasion. Key nodes include:

• • JAK/STAT pathway:
• • SOCS1/SOCS3 upregulation inhibits IFN-gamma signaling.
• • STAT1 degradation reduces iNOS expression.
• • NF-kB pathway:
• • GP63 cleaves p65, impairing pro-inflammatory gene transcription.
• • Inhibition of IKK complex reduces cytokine production.
• • PI3K/AKT/mTOR pathway:
• • Activation promotes macrophage survival and inhibits apoptosis.
• • mTOR inhibition enhances autophagy, which can kill parasites.
• • MAPK pathway:
• • ERK1/2 activation by Leishmania promotes IL-10 production.
• • p38 MAPK inhibition reduces TNF-alpha secretion.
• • Wnt/beta-catenin pathway:
• • Activation in macrophages suppresses inflammatory responses.
• • May promote parasite persistence in chronic lesions.

These networks are attractive targets for host-directed therapies and gene-edited cell models.

Leishmania research relies on both parasite cell lines and host cell models. Key parasite lines include:

• • Host cell models include:
• • THP-1 macrophages: Differentiated with PMA, widely used for infection studies.
• • Bone marrow-derived macrophages (BMDMs): Primary cells for ex vivo infection.
• • Human monocyte-derived macrophages (hMDMs): Relevant for human immune responses.
• • Organoids: Emerging 3D models of skin or liver can mimic tissue-specific infection and granuloma formation, though still under development.

Organoid advantages: Better recapitulate tissue architecture, cell-cell interactions, and drug penetration; useful for studying CL skin lesions and VL liver/spleen pathology.

Animal models are essential for studying pathogenesis, immunity, and drug efficacy. Common models include:

• • Mouse models:
• • BALB/c mice: Susceptible to L. major, develop progressive CL.
• • C57BL/6 mice: Resistant, develop self-healing lesions.
• • CBA mice: Susceptible to L. donovani, model VL.
• • Humanized mice: Engrafted with human hematopoietic stem cells for human immune response studies.
• • Hamster models:
• • Golden hamsters: Highly susceptible to L. donovani, develop fatal VL with hepatosplenomegaly.
• • Dog models:
• • Natural reservoir for L. infantum, develop canine VL similar to human disease.
• • Non-human primates:
• • Macaques: Used for vaccine and drug testing, but limited by cost and ethics.
• • Induced models:
• • Genetically engineered mouse models (GEMMs) with knockout of immune genes (e.g., IFN-gamma, IL-12) to study susceptibility.
• • Patient-derived xenografts (PDX) are not applicable for Leishmania due to species specificity, but humanized mice serve as a surrogate.

These models help evaluate drug efficacy, vaccine candidates, and immune correlates of protection.

CRISPR-Cas9 technology has revolutionized Leishmania research by enabling precise gene knockouts, knock-ins, and point mutations. Isogenic cell lines are generated by editing the parasite genome or host cells to study gene function and drug resistance.

• • Examples of gene-edited models:
• • Leishmania knockout lines:
• • LdMT knockout: Generated by CRISPR, confirms role in antimony resistance.
• • TryR knockout: Validates trypanothione reductase as a drug target.
• • GP63 knockout: Reduces virulence and immune evasion.
• • Leishmania knock-in lines:
• • Reporter lines: Expressing GFP or luciferase for real-time infection monitoring.
• • Point mutation knock-ins: e.g., LdMT T221I to mimic clinical resistance.
• • Host cell models:
• • CRISPR knockout of host genes (e.g., NLRP3, IL-10) in THP-1 or BMDMs to study immune pathways.
• • Knock-in of human susceptibility alleles (e.g., SLC11A1 variants) to model genetic predisposition.

Commercially available, sequence-verified gene-edited cell models accelerate research by providing reproducible, validated tools. These models are engineered using CRISPR and quality-controlled to ensure consistent performance in drug discovery and functional genomics.

Gene-edited Leishmania and host cell lines enable functional genomics studies to validate drug targets and understand pathogenesis. Examples:

• • Knockout of parasite genes:
• • LdMT: Confirms role in antimony transport; knockout lines are hypersensitive to antimony.
• • TryR: Essential for parasite survival; knockout is lethal unless complemented, validating it as a drug target.
• • LmjF.36.0120: Knockout reduces virulence in mouse models.
• • Knock-in of reporter genes:
• • GFP-expressing L. donovani allows real-time tracking of parasite burden in macrophages and mice.
• • Luciferase-expressing L. major enables high-throughput drug screening.
• • Host gene editing:
• • CRISPR knockout of IFN-gamma receptor in macrophages abolishes parasite killing, confirming its essential role.
• • Knockout of autophagy genes (e.g., ATG5) increases parasite survival, highlighting autophagy as a defense mechanism.

These models provide mechanistic insights and prioritize targets for drug development.

Isogenic pairs of Leishmania lines (wild-type vs. knockout or mutant) are powerful tools for drug screening and resistance studies.

• • Isogenic pair screens:
• • Compare drug sensitivity between LdMT wild-type and knockout lines to identify compounds that bypass resistance.
• • Screen antimony-resistant clinical isolates against CRISPR-engineered lines to validate resistance mechanisms.
• • Resistance modeling:
• • Generate miltefosine-resistant lines by CRISPR knock-in of AQP1 mutations, then test new drugs.
• • Use host cell knockouts (e.g., ABC transporters) to study drug efflux and intracellular drug concentrations.
• • High-throughput screening:
• • Reporter parasites (e.g., luciferase) enable automated screening of compound libraries.
• • Host cell lines with fluorescent reporters (e.g., NF-kB-GFP) measure anti-inflammatory drug effects.

These applications accelerate the discovery of new therapeutics and overcome drug resistance.

CRISPR synthetic lethality screens in Leishmania and host cells identify genetic dependencies and biomarkers.

• • Parasite synthetic lethality:
• • Genome-wide CRISPR knockout libraries in L. mexicana identify genes essential for survival in macrophages.
• • Screens under drug pressure reveal resistance-conferring genes (e.g., LdMT, AQP1).
• • Host-directed screens:
• • CRISPR knockout of human kinases in THP-1 cells identifies host factors required for parasite entry or survival.
• • Synthetic lethal interactions between host genes and parasite infection reveal new therapeutic targets.
• • Biomarker validation:
• • Gene expression signatures from edited lines correlate with clinical outcomes (e.g., treatment response).
• • Circulating parasite DNA or host microRNAs serve as non-invasive biomarkers.

These approaches uncover novel biomarkers for diagnosis, prognosis, and treatment monitoring.

Note: TCGA, COSMIC, and NCI are cancer-focused and not directly relevant to leishmaniasis. However, host cell models may intersect with cancer research in macrophage biology.